The FDA has accepted pembrolizumab for the first-line therapy of sure HER2-negative gastric and gastroesophageal junction cancers.
The U.S. Meals and Drug Administration (FDA)...
New analysis has revealed how metabolic modifications spurred by fatty acids contribute to the transformation of cells into irregular variations of themselves which...
